Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2003

01-03-2003 | Originales

The addition of oxaliplatin to the mayo clinic schedule significantly increases its toxicity: a retrospective analysis of patients with advanced colorectal cancer

Authors: Regina Gironés Sarrió, Eva Calabuig Muñoz, Jorge Aparicio Urtasun, Pedro López Tendero, Ana Yuste Izquierdo, Ángel Segura Huerta

Published in: Clinical and Translational Oncology | Issue 2/2003

Login to get access
Metadata
Title
The addition of oxaliplatin to the mayo clinic schedule significantly increases its toxicity: a retrospective analysis of patients with advanced colorectal cancer
Authors
Regina Gironés Sarrió
Eva Calabuig Muñoz
Jorge Aparicio Urtasun
Pedro López Tendero
Ana Yuste Izquierdo
Ángel Segura Huerta
Publication date
01-03-2003
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2003
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02728201

Other articles of this Issue 2/2003

Clinical and Translational Oncology 2/2003 Go to the issue

Originales

Bioquimioterapia ambulatoria con cisplatino, dacarbacina, interleucina-2 e interferón-alfa en pacientes con melanoma avanzado. Estudio multicéntrico en 44 pacientes

Notas Clínicas

Secretion of alfafetoprotein by lung cancer

Sección Docente

Introduction to the teaching course in surgical oncology

Sección Docente

Selective biopsy of the sentinel node: technique and present state in the different tumors

Notas Clínicas

Fibromatosis agresiva en un varón adolescente

Revisiones

Valoración del paciente que solicita muerte asistida
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits